

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-12 (cancelled).

Claim 13 (currently amended): ~~A composition comprising an~~ An isolated antibody which ~~selectively~~ specifically binds to ~~an isolated polypeptide selected from the group consisting of:~~

a) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising,~~
protein ~~comprises~~ comprising the amino acid sequence of SEQ ID NO:2 or a
fragment thereof;

wherein said antibody binds specifically to an epitope in the amino acid sequence
of SEQ ID NO:2 or a fragment thereof.

b) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising the amino
acid sequence of~~ SEQ ID NO:4, or a fragment thereof;

c) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising the amino
acid sequence of~~ SEQ ID NO:6, or a fragment thereof;

d) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising the amino
acid sequence of~~ SEQ ID NO:8, or a fragment thereof;

e) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising the amino
acid sequence of~~ SEQ ID NO:10, or a fragment thereof;

f) ~~a polypeptide encoding a~~ TNF-R1-DD ligand protein ~~comprising the amino acid
sequence of~~ SEQ ID NO:12, or a fragment thereof;

~~g) a polypeptide encoding a TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:14, or a fragment thereof;~~

~~h) a polypeptide encoding a TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:16, or a fragment thereof; and~~

~~i) a polypeptide encoding a TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:18, or a fragment thereof.~~

Claims 14-51 (cancelled)

52. (newly added): The antibody of claim 13, wherein said antibody is a neutralizing antibody.

53. (newly added): The antibody of claim 13, wherein said antibody blocks binding of TNF-R1-DD to a polypeptide TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:2.

54. (newly added): The antibody of claim 13, wherein said antibody is a polyclonal antibody.

55. (newly added): The antibody of claim 13, wherein said antibody is a monoclonal antibody.

56. (newly added): The antibody of claim 13, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2.

57. (newly added): The antibody of claim 13, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:12.

58. (newly added): The antibody of claim 13, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:16.

59. (newly added): A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.

60. (newly added): A neutralizing antibody that binds specifically to a TNF-R1-DD ligand protein,

wherein said TNF-R1-DD ligand protein comprises the amino acid sequence of SEQ ID NO:2 or a fragment thereof;

wherein said antibody binds specifically to an epitope in the amino acid sequence of SEQ ID NO:2;

and wherein said neutralizing antibody blocks binding of TNF-R1-DD to a TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:2.

61. (newly added): The antibody of claim 60, wherein said antibody is an isolated antibody.

62. (newly added): A pharmaceutical composition comprising the composition of claim 60 and a pharmaceutically acceptable carrier.

63. (newly added) An antibody obtained using as an immunogen TNF-R1-DD ligand protein, wherein said TNF-R1-DD ligand protein comprises the amino acid sequence of SEQ ID NO:2.

64. (newly added): The antibody of claim 63, wherein said antibody is obtained using as an immunogen a protein with tyrosine residues replaced with sulfated tyrosine residues.

65. (newly added): The antibody of claim 63, wherein said immunogen is conjugated to a hapten.

66. (newly added): The antibody of claim 65, wherein said hapten is keyhole limpet hemocyanin (KLH).